deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT03161353

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHERGain)

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study

Sponsor: MedSIR

Conditions Breast Cancer
Interventions Carboplatin Docetaxel Herceptin Letrozole Perjeta Tamoxifen
Updated 20 times since 2017 Last updated: Apr 22, 2025 Started: Jun 26, 2017 Primary completion: Nov 1, 2023 Completion: Nov 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by MedSIR and has accumulated 20 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Jul 2020 · 10 months · monthly snapshot~Jul 2020 – ~Dec 2020 · 5 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jul 2022 · 15 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jan 2024 · 11 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Completed → Active Not Recruiting

▶ Show 15 earlier versions

  1. Jan 2024 — Mar 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Feb 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Jul 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Sep 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Apr 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  11. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  12. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  13. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  14. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Jun 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MedSIR
Data source: MedSIR

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Badalona, Spain , Barcelona, Spain , Bologna, Italy , Brindisi, Italy , Brussels, Belgium , Burgos, Spain , Castelló, Spain , Clermont-Ferrand, France , Cremona, Italy and 33 more locations